These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31271450)

  • 1. Interleukin 9 alterations linked to alzheimer disease in african americans.
    Wharton W; Kollhoff AL; Gangishetti U; Verble DD; Upadhya S; Zetterberg H; Kumar V; Watts KD; Kippels AJ; Gearing M; Howell JC; Parker MW; Hu WT
    Ann Neurol; 2019 Sep; 86(3):407-418. PubMed ID: 31271450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.
    Howell JC; Watts KD; Parker MW; Wu J; Kollhoff A; Wingo TS; Dorbin CD; Qiu D; Hu WT
    Alzheimers Res Ther; 2017 Nov; 9(1):88. PubMed ID: 29096697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.
    Modeste ES; Ping L; Watson CM; Duong DM; Dammer EB; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2023 Jul; 18(1):48. PubMed ID: 37468915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race modifies default mode connectivity in Alzheimer's disease.
    Misiura MB; Howell JC; Wu J; Qiu D; Parker MW; Turner JA; Hu WT
    Transl Neurodegener; 2020; 9():8. PubMed ID: 32099645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment.
    Garrett SL; McDaniel D; Obideen M; Trammell AR; Shaw LM; Goldstein FC; Hajjar I
    JAMA Netw Open; 2019 Dec; 2(12):e1917363. PubMed ID: 31834392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived Stress is Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in African Americans with Mild Cognitive Impairment.
    Trammell AR; McDaniel DJ; Obideen M; Okafor M; Thomas TL; Goldstein FC; Shaw LM; Hajjar IM
    J Alzheimers Dis; 2020; 77(2):843-853. PubMed ID: 32741810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study.
    Kumar VV; Huang H; Zhao L; Verble DD; Nutaitis A; Tharwani SD; Brown AL; Zetterberg H; Hu W; Shin R; Kehoe PG; Quyyumi A; Nocera J; Kippels A; Wharton W
    J Alzheimers Dis; 2020; 75(1):109-117. PubMed ID: 32280088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
    Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
    JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment.
    Giannisis A; Al-Grety A; Carlsson H; Howell JC; Hu WT; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2023 Jul; 15(1):119. PubMed ID: 37400888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing fluid biomarkers of Alzheimer's disease between African American or Black African and white groups: A systematic review and meta-analysis.
    Chaudhry A; Rizig M
    J Neurol Sci; 2021 Feb; 421():117270. PubMed ID: 33349466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
    Bonomi S; Lu R; Schindler SE; Bui Q; Lah JJ; Wolk D; Gleason CE; Sperling R; Roberson ED; Levey AI; Shaw L; Van Hulle C; Benzinger T; Adams M; Manzanares C; Qiu D; Hassenstab J; Moulder KL; Balls-Berry JE; Johnson K; Johnson SC; Murchison CF; Luo J; Gremminger E; Agboola F; Grant EA; Hornbeck R; Massoumzadeh P; Keefe S; Dierker D; Gray J; Henson RL; Streitz M; Mechanic-Hamilton D; Morris JC; Xiong C
    Ann Neurol; 2024 Mar; 95(3):495-506. PubMed ID: 38038976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment.
    Johansson P; Almqvist EG; Wallin A; Johansson JO; Andreasson U; Blennow K; Zetterberg H; Svensson J
    PLoS One; 2017; 12(5):e0176760. PubMed ID: 28464009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment.
    Schedin-Weiss S; Gaunitz S; Sui P; Chen Q; Haslam SM; Blennow K; Winblad B; Dell A; Tjernberg LO
    FEBS J; 2020 Aug; 287(15):3221-3234. PubMed ID: 31889402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.